Answers are grounded in this paper and cite their sources.
Background Federal reforms have expanded flexibility in methadone take-home dosing for patients in opioid treatment programs (OTPs). Though evidence increasingly supports more flexible, patient-centered methadone treatment, OTPs have expressed a variety of concerns about expanded take-home doses. This study used an established organizational-change framework to examine sources of OTPs’ concerns in response to flexible methadone take-home policies and proposes research on a model of managerial strategies for addressing them. Methods We analyzed qualitative interview data from 44 key informants at 19 OTPs in New York State, including program directors, clinical supervisors, counselors, and medical directors. Interviews examined organizational responses to COVID-19-related changes in methadone treatment. We used qualitative coding and thematic analysis to identify sources of concern about changes in take-home dosing policy and practice. Results Concerns about flexible take-home dosing reflected four major sources: lack of information or misunderstanding about policy changes; perceived lack of participation in planning or implementation; perceived inability to change or low tolerance for change; and perceived threats to professional values, including concerns for patient safety and quality of care. More specifically, respondents’ concerns included uncertainty about regulations, limited voice in implementation decisions, discomfort with reduced reliance on traditional clinic-based monitoring, and worries about diversion, overdose, liability, and patient safety. Conclusions OTPs expressed a variety of concerns about methadone take-home doses. Different sources of concern require different implementation strategies, including education, participation, facilitation, and negotiation. As methadone treatment moves toward more flexible and patient-centered models, we need research to support the efforts of OTP leaders, staff members, and policymakers to diagnose sources of variation in response to changes and tailor implementation accordingly. Clinical trial number Not applicable. Trial registration Not applicable.
No takes yet. Share an insight, caveat, or question.
D’Aunno et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: